The US President's Emergency Plan for AIDS Relief has been a cornerstone of global HIV/AIDS prevention, care and treatment ...

Gilead Sciences has allocated USD 200 million to potentially settle with federal prosecutors to resolve an investigation into ...

Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal investigation.

The major backer of the lenacapavir roll-out is assuring nervous researchers that they will keep their part of funding ...

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

The FDA has accepted under Priority Review the NDA for lenacapavir for the prevention of HIV as pre-exposure prophylaxis.

Researchers from the Max Planck Institute of Biochemistry have discovered the mechanism behind an important step in the life ...

A revolutionary advancement in HIV prevention technology stands at a critical crossroads as recent policy decisions threaten ...

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

Several protesters were arrested Wednesday after U.S. Agency for International Development workers were told via a text ...

It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and regulatory updates were in focus. Recap of the Week’s ...

A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...